It’s difficult to imagine what will break it. It’s had the CE mark announced. It’s had other regulatory filings. It’s even announced today first sales. Yet no change. Just huge volumes being bought and yes SOLD!
Can’t imagine what will break this and cause the stock to rerate.
Plenty of other biotech stocks have zero revenue but enjoy plenty of rerates. Some have only small phase 1 trials and nothing more. And they bounce hard.
Not here unfortunately. Nothing. Just more of the same.
Ann: OncoSil achieves first commercial sale, page-22
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $18.92K | 1.705M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 13619110 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 5063491 | 9 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |